Targets › GGPS1
2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 4; Oncology, Gastroenterology; next expected readout Dec 2026.
Catalyzes the trans-addition of the three molecules of IPP onto DMAPP to form geranylgeranyl pyrophosphate, an important precursor of carotenoids and geranylated proteins. (UniProt, O95749)
Open in Phaseline: the race on GGPS1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Bahria University | alendronate sodium powder Bisphosphonate; inhibits farnesyl pyrophosphate synthase, blocking osteoclast bone resorpt | GGPS1 | Phase 4 | Alveolar Bone Loss Associated Chronic Periodontitis | Sep 2027 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | Zoledronic Acid-loaded Bone Cement Farnesyl pyrophosphate synthase inhibitor; bisphosphonate that inhibits osteoclast functio | GGPS1 | Phase 2 | Giant Cell Tumor of Bone | Dec 2026 |
Giant Cell Tumor of Bone (1) Alveolar Bone Loss Associated Chronic Periodontitis (1)
small molecule (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (1) Bahria University (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.